A5082032876- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Inflammatory Biomarkers in Disease Prognosis
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Treatments and Studies
- Pediatric Hepatobiliary Diseases and Treatments
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Hepatitis C virus research
- Liver Diseases and Immunity
- Colorectal Cancer Screening and Detection
- Cancer Mechanisms and Therapy
- COVID-19 Clinical Research Studies
- Cancer, Lipids, and Metabolism
- Neurological and metabolic disorders
- Polyomavirus and related diseases
- Ferroptosis and cancer prognosis
- Neutropenia and Cancer Infections
- Peripheral Nerve Disorders
- Bladder and Urothelial Cancer Treatments
- Takotsubo Cardiomyopathy and Associated Phenomena
- Genetic factors in colorectal cancer
Icahn School of Medicine at Mount Sinai
2019-2024
Tisch Cancer Institute
2020-2024
Tisch Hospital
2020-2024
Mount Sinai Hospital
2020-2022
Mount Sinai Hospital
2021-2022
Pitié-Salpêtrière Hospital
2022
Sorbonne Université
2022
Cancer Institute (WIA)
2020
Illinois College
2017
Albert Einstein College of Medicine
2017
Observational data suggest an acquired prothrombotic state may contribute to the pathophysiology of COVID-19. These include elevated D-dimers observed among many COVID-19 patients. We present a retrospective analysis admission D-dimer, and D-dimer trends, 1065 adult hospitalized patients, across 6 New York Hospitals. The primary outcome was all-cause mortality. Secondary outcomes were intubation venous thromboembolism (VTE). Three-hundred-thirteen patients (29.4%) died, 319 (30.0%) required...
Abstract Background Currently, there are no recognized or validated biomarkers to identify hepatocellular carcinoma patients (HCC) likely benefit from anti–PD‐1 therapy. We evaluated the relationship between neutrophil‐lymphocyte ratio (NLR) and platelet‐lymphocyte (PLR) survival outcomes, pretreatment after three doses (posttreatment) of nivolumab in HCC patients. Methods Medical records treated with June 2016 July 2018 were reviewed. Kaplan‐Meier analysis log‐rank test used calculate...
Systemic inflammation is a hallmark of cancer, and it has pivotal role in hepatocellular carcinoma (HCC) development progression. We conducted retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence neutrophiles to lymphocytes ratio (NLR), platelets (PLR), prognostic nutritional index (PNI) on overall (OS), progression free survival (PFS), radiologic responses. In our treated with immunotherapy, median OS PFS...
Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and clinical development of ICI HCC. We tested accuracy albumin-bilirubin (ALBI) grade as an alternative prognostic biomarker Child-Turcotte-Pugh (CTP). In a prospectively maintained multi-centre dataset HCC patients, we assessed safety efficacy across varying levels dysfunction...
Background Nivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment a real-world setting lacking. Patients methods We performed an international, multicenter observational study to confirm safety efficacy nivolumab 233 patients treated outside clinical trials from eight centers North America, Europe Asia. Results received for Barcelona Clinic Liver Cancer stage C (n = 191, 92.0%) Child-Pugh (CP)...
Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI can impact immunotherapy efficacy across indications; however, the effect of ATB undefined in HCC.In a large international cohort 450 recipients from Europe, North America, and Asia, we categorized patients according timing focusing on exposure within -30 +30 days (early period [EIOP]). EIOP was evaluated association with...
Different approaches are available after the progression of disease (PD) to immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC), including continuation ICI, treatment switching tyrosine kinase (TKIs) and cessation anticancer therapy. We sought characterise relationship between radiological patterns survival post-ICI, also appraising strategies.
The impact of corticosteroid therapy (CT) on efficacy immune checkpoint inhibitors (ICI) is undefined in hepatocellular carcinoma (HCC). We evaluated whether CT administered at baseline (bCT) or concurrently with ICI (cCT) influences overall (OS), progression-free survival (PFS) and response rates (ORR) 341 patients collected across 3 continents. Of 304 eligible patients, 78 (26%) received > 10 mg prednisone equivalent daily either as bCT (n=14, 5%) cCT (n=64, 21%). Indications for...
BACKGROUND A well-recognized class effect of immune checkpoint inhibitors (ICI) is immune-related adverse events (IrAEs) ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation ICI. Deaths are reported in < 5% patients treated with There are, however, no reliable markers predict the onset and severity IrAEs. We tested association between neutrophil-lymphocyte ratio (NLR) platelet-lymphocyte (PLR) at baseline development clinically...
Background: Early-onset colorectal cancer (EO-CRC) is defined as diagnosed before the age of 50 years, and its incidence has been increasing over last decade, now accounting for 10% all new CRC diagnoses. Average-onset (AO-CRC) shown a steady decline in related mortality past 20 years. The disparities outcomes overall survival (OS) between EO-CRC AO-CRC are controversial. Our study compared OS cause-specific (CSS) metastatic (mEO-CRC) (mAO-CRC) identified associated factors. Methods: Data on...
Abstract The availability of immune checkpoint inhibitors (ICIs) for the management advanced hepatocellular cancer (HCC) has changed treatment paradigm. There are emerging questions regarding efficacy subsequent anticancer therapies. primary aim this retrospective, multicenter study was to examine types received after ICIs and assess impact on post‐ICI survival. We established an international consortium 11 tertiary‐care referral centers located in USA (n = 249), Europe 74), Asia 97),...
Background: Antibiotic exposure has been associated with worse outcomes immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption of the gut microbiome. Other commonly prescribed medications, such as proton pump (PPIs) and histamine-2-receptor antagonists (H2RAs), are also known disrupt microbiome, but data on their association ICI conflicting. Methods: We conducted a retrospective, multicenter, international cohort study including 314 hepatocellular carcinoma (HCC)...
e15549 Background: Early-onset colorectal cancer (EO-CRC) is defined as diagnosed before age 50 and its incidence has been increasing during the last decade. Average-onset (AO-CRC) presented a steady decline in related mortality over past 20 years. There controversy surrounding disparities outcomes overall survival (OS) EO-CRC vs. AO-CRC. Our study compared OS cause-specific (CSS) between metastatic (mEO-CRC) AO-CRC (mAO-CRC) identified associated factors. Methods: Data on patient...
Neoadjuvant chemotherapy (NACT) is increasingly being used in the management of locally advanced biliary tract cancer (BTC). The evidence suggests a contributing role tumor infiltrating immune cells prognosis and response. We set out to characterize modulation microenvironment BTC following NACT.
Introduction: Racial disparities in gastric cancer outcomes, including stage at diagnosis and overall survival, continue to affect Hispanic non-Hispanic populations. This study aims evaluate these across different racial groups. Patients methods: We conducted a retrospective cohort using SEER data from 2018 2021, 18,984 patients diagnosed with cancer. were selected based on ICD-O-3 codes for “stomach” malignant behavior. Using ordered logistic regression, the association between race was...
484 Background: Immunotherapy (IO) response rates in advanced hepatocellular carcinoma (HCC) are less than 20%. The microbiome has been shown to mediate IO experimental models, and clinical studies have observed that antibiotics, especially prior initiation, associated with reduced response. We reasoned commonly prescribed antacid medications, such as proton pump inhibitors (PPIs) histamine receptor antagonists (H2RAs), which known influence the microbiome, may also Methods: This is a...